Education
About Us
Working with TipRanks
Follow Us
Alligator Bioscience AB (SE:ATORX)
:ATORX
ATORX Stock Chart & Stats
kr0.34
-kr0.03(-72.12%)
At close: 4:00 PM EST
kr0.34
-kr0.03(-72.12%)
Day’s Range― - ―
52-Week Rangekr0.17 - kr63.16
Previous CloseN/A
Volume998.30M
Average Volume (3M)1.75M
Market Cap
kr88.53M
Enterprise Valuekr18.55M
Total Cash (Recent Filing)kr25.07M
Total Debt (Recent Filing)kr37.19M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding497,347,000
10 Day Avg. Volume1,169,449
30 Day Avg. Volume1,745,933
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-16.56
Price to Sales (P/S)37.43
P/FCF Ratio-10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Partnership-driven Business ModelA licensing and partnering model limits the need for late-stage commercialization capital and leverages partners' global capabilities. This reduces long-term capex and commercialization risk, enabling the company to focus R&D resources and monetize assets through milestones and royalties.
Focused Immunotherapy ExpertiseConcentration on antibody-based cancer immunotherapies aligns with a durable, growing oncology market and high partner interest. Specialized scientific expertise and pipeline focus increase the likelihood of attractive out-licensing deals and strategic collaborations over the medium term.
Improving Gross MarginA materially improved gross margin suggests progress in cost of goods or revenue mix, which can enhance long-term operating leverage if sustained. For a partnering-focused biotech, higher gross margin increases the share of net proceeds available for development and partner negotiations.
Bears Say
Severe Cash BurnVery large negative operating and free cash flows create persistent financing dependence and dilution risk. Over a multi-quarter horizon this undermines run-rate stability, forces frequent capital raises or deal-dependence, and increases execution risk for clinical programs absent new funding.
Negative Shareholders' EquityA negative equity position is a structural solvency warning that constrains financing options, complicates leverage calculations, and raises refinancing risk. Lenders and partners may demand stricter terms, increasing cost of capital and limiting strategic flexibility over the medium term.
Sharp Revenue Decline And Persistent LossesA material revenue drop combined with deep, ongoing operating losses signals an unstable commercial progress and weak near-term cash conversion. This erodes bargaining power with partners, raises execution risk for pipeline advancement, and increases likelihood of future financing dependency.
Alligator Bioscience AB News
ATORX FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest stock price was kr0.17 and its highest was kr63.16 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is kr88.53M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is May 05, 2026 which is in 77 days.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on Feb 12, 2026. The company reported -kr0.663 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.663.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 497,347,000 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of -kr0.663 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.523%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in SE:ATORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Technical Analysis
Alzinova AB
―
Nanologica AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
NextCell Pharma AB
―